$2.78
-0.11-3.81%
At close: -
$2.75
-0.03-1.09%
After Hours: 7:58 PM EDT
Comments
Loading...
ImmunityBio Analyst Ratings and Price Targets | NASDAQ:IBRX | Benzinga
ImmunityBio Inc has a consensus price target of $13.54 based on the ratings of 7 analysts. The high is $30 issued by D. Boral Capital on April 15, 2025. The low is $4.75 issued by Piper Sandler on August 19, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital on April 15, 2025, April 9, 2025, and March 31, 2025, respectively. With an average price target of $30 between D. Boral Capital, there's an implied 990.99% upside for ImmunityBio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
HC Wainwright & Co.
BTIG
EF Hutton
1calculated from analyst ratings
Analyst Ratings for ImmunityBio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/15/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 190.93% | HC Wainwright & Co. | Andres Maldonado37% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 03/06/2025 | Buy Now | 190.93% | HC Wainwright & Co. | Andrew Fein53% | → $8 | Initiates | → Buy | Get Alert |
| 03/03/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 02/19/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 01/30/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 01/27/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 01/16/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | 118.2% | BTIG | Justin Zelin41% | → $6 | Initiates | → Buy | Get Alert |
| 01/06/2025 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 11/21/2024 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 11/19/2024 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 990.99% | D. Boral Capital | Jason Kolbert39% | $30 → $30 | Maintains | Buy | Get Alert |
| 10/23/2024 | Buy Now | 990.99% | EF Hutton | Jason Kolbert39% | → $30 | Initiates | → Buy | Get Alert |
| 08/19/2024 | Buy Now | 72.74% | Piper Sandler | Joseph Catanzaro41% | $6 → $4.75 | Maintains | Neutral | Get Alert |
| 04/29/2024 | Buy Now | 118.2% | Piper Sandler | Joseph Catanzaro41% | $5 → $6 | Maintains | Neutral | Get Alert |
| 03/25/2024 | Buy Now | 81.83% | Piper Sandler | Joseph Catanzaro41% | $4 → $5 | Maintains | Neutral | Get Alert |
| 05/12/2023 | Buy Now | 45.47% | Piper Sandler | Joseph Catanzaro41% | $10 → $4 | Downgrade | Overweight → Neutral | Get Alert |
| 08/03/2022 | Buy Now | 190.93% | Jefferies | Kelly Shi37% | → $8 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for ImmunityBio (IBRX) stock?
The latest price target for ImmunityBio (NASDAQ:IBRX) was reported by D. Boral Capital on April 15, 2025. The analyst firm set a price target for $30.00 expecting IBRX to rise to within 12 months (a possible 990.99% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ImmunityBio (IBRX)?
The latest analyst rating for ImmunityBio (NASDAQ:IBRX) was provided by D. Boral Capital, and ImmunityBio maintained their buy rating.
When was the last upgrade for ImmunityBio (IBRX)?
There is no last upgrade for ImmunityBio
When was the last downgrade for ImmunityBio (IBRX)?
The last downgrade for ImmunityBio Inc happened on May 12, 2023 when Piper Sandler changed their price target from $10 to $4 for ImmunityBio Inc.
When is the next analyst rating going to be posted or updated for ImmunityBio (IBRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunityBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunityBio was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.
Is the Analyst Rating ImmunityBio (IBRX) correct?
While ratings are subjective and will change, the latest ImmunityBio (IBRX) rating was a maintained with a price target of $30.00 to $30.00. The current price ImmunityBio (IBRX) is trading at is $2.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.